Thoracic impedance

1. Empagliflozin increases thoracic impedance in humans (+3.1±0.85% vs +0.14±1.2%, p<0.05).

   “The primary endpoint, the mean change in TI at 24 weeks after the start of intervention, was greater in the empagliflozin group (+3.1±0.85% in the empagliflozin group, +0.14±1.2% in the placebo group, p<0.05).”

   Human trialpatients with type 2 diabetes treated with an implantable cardioverter-defibrillator10 mg once daily24 weeksn = 61

   Effect of Empagliflozin on Device-Measured Thoracic Impedance in Patients with Type 2 diabetes treated with an implantable cardioverter-defibrillator: A subanalysis of the EMPA-ICD trial.

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on Empagliflozin